Comparative effects of haemodialysis and haemofiltration on plasma atrial natriuretic peptide.

The effects of 4 h haemodialysis (15 patients) or 4 h haemofiltration (five patients) on plasma concentrations of atrial natriuretic peptide (ANP) were compared by means of a sensitive radioreceptor binding assay, and related to accompanying changes in body weight, blood pressure and plasma renin activity. Before dialysis, plasma ANP concentrations were considerably elevated: haemodialysis group 10-484 pmol/l (mean 156 pmol/l); haemofiltration group 72-320 pmol/l (mean 170 pmol/l). Although plasma concentrations of ANP fell markedly with treatment in both groups: post-haemodialysis 2-187 pmol/l (mean 67 pmol/l); post-haemofiltration 47-135 pmol/l (mean 79 pmol/l), after treatment it remained above the normal range in 14 of the 20 patients. Pretreatment plasma ANP was related to systolic blood pressure (r = 0.459; P less than 0.05) but bore no relationship to mean or diastolic blood pressure, or plasma renin activity. The fall in plasma ANP concentration during treatment correlated with the postural blood pressure drop after dialysis (r = 0.505; P less than 0.05), but was unrelated to changes in weight or plasma renin activity with haemodialysis or haemofiltration. Plasma ANP concentrations rose rapidly again in the 60 min after dialysis treatment, without change in body weight. These results show that high levels of biologically active ANP circulate in end-stage renal disease. The fact that these are not reduced to normal by haemodialysis or haemofiltration, despite restoration to normovolaemic or hypovolaemic state, suggests that the increased levels of ANP in end-stage renal failure are due to both hypervolaemia and other factors, which may include occult cardiac dysfunction and loss of renal clearance.

[1]  W. Kratz,et al.  Optimising of hemodiafiltration with modern membranes? , 1985, Contributions to nephrology.

[2]  J. Smits,et al.  Failure of atriopeptin II to cause arterial vasodilation in the conscious rat. , 1985, Circulation research.

[3]  I. Sarda,et al.  Functional-morphological studies on in vitro cardionatrin release. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[4]  C. Zoccali,et al.  Effect of ultrafiltration on plasma concentrations of atrial natriuretic peptide in haemodialysis patients. , 1986, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  P. Erne,et al.  The vasodilator potency of atrial natriuretic peptide in man. , 1987, Circulation.

[6]  P. Erne,et al.  Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. , 1986, The New England journal of medicine.

[7]  D. Adu,et al.  Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis. , 1986, Clinical science.

[8]  R. G. Walker,et al.  Exaggerated responsiveness of immunoreactive atrial natriuretic peptide to saline infusion in chronic renal failure. , 1987, Clinical science.

[9]  P. Erne,et al.  Human cardiac plasma concentrations of atrial natriuretic peptide quantified by radioreceptor assay. , 1985, Biochemical and biophysical research communications.

[10]  D. Ganten,et al.  Atrial natriuretic factor—a circulating hormone stimulated by volume loading , 1985, Nature.

[11]  N. Glorioso,et al.  Plasma clearance and effects of alpha-hANP infused in patients with end-stage renal failure. , 1988, The American journal of physiology.

[12]  P. Weidmann,et al.  Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. , 1987, Kidney international.

[13]  R. Maiorca,et al.  Plasma concentrations of atrial natriuretic peptide in relation to body fluid status in chronic uraemia. , 1987, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  K. Imataka,et al.  Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. , 1987, Hypertension.

[15]  J. Laragh,et al.  The renin system: Variations in man measured by radioimmunoassay or bioassay. , 1972, Kidney international.

[16]  T. Tulassay,et al.  ATRIAL NATRIURETIC PEPTIDE IN PLASMA OF VOLUME-OVERLOADED CHILDREN WITH CHRONIC RENAL FAILURE , 1985, The Lancet.

[17]  L. Lins,et al.  Cardiac performance in various stages of renal failure. , 1984, British heart journal.

[18]  R. Cuneo,et al.  Studies on the secretion, metabolism and action of atrial natriuretic peptide in man. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[19]  A. Richards,et al.  Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. , 1987, Journal of hypertension.

[20]  A. Katz,et al.  Metabolism of polypeptide hormones by the normal kidney and in uremia. , 1978, Nephron.

[21]  S. Bloom,et al.  Effect of haemodialysis on plasma concentrations of atrial natriuretic peptide in adult patients with chronic renal failure. , 1986, The Journal of endocrinology.

[22]  J. Mitchell,et al.  Effect of hemodialysis on left ventricular function. Dissociation of changes in filling volume and in contractile state. , 1983, The Journal of clinical investigation.

[23]  S. Bloom,et al.  The plasma release of atrial natriuretic peptide in man. , 1986, Clinical science.

[24]  K. Kangawa,et al.  Plasma concentration of human atrial natriuretic polypeptide in patients with impaired renal function. , 1987, Clinical nephrology.

[25]  H. Zurcher-Neely,et al.  Inactivation of atrial natriuretic factor by the renal brush border. , 1987, Biochimica et biophysica acta.